diagnostic

Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…

1 month ago

LifeLabs Named Canadas Most Trusted Health Diagnostic Service Provider for Third Consecutive Year by BrandSpark Most Trusted Awards

Toronto, Ontario, Jan. 21, 2025 (GLOBE NEWSWIRE) -- LifeLabs is proud to announce that it has been named Canada’s Most…

2 months ago

Effective 02/07/2025, Interpace Diagnostics to No Longer Offer PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX:…

2 months ago

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

November 03, 2024 17:03 ET | Source: Telix Pharmaceuticals Limited MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals…

4 months ago